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OBJECTIVES The effects of ximelagatran, an oral direct thrombin inhibitor (DTI), recombinant hirudin
(r-hirudin) and enoxaparin on thrombin generation and platelet activation were studied in
humans.
BACKGROUND Recombinant hirudin (parenteral DTI) and enoxaparin (low molecular weight heparin) have
been demonstrated to be clinically effective in acute coronary syndromes. Ximelagatran is
currently under investigation for the prevention and treatment of thromboembolism. The
shed blood model allows for the study of thrombin generation and platelet activation in
humans in vivo.
METHODS This was an open-label, parallel-group study involving 120 healthy male volunteers random-
ized to receive one of three oral doses of ximelagatran (15, 30 or 60 mg), r-hirudin
(intravenous) or enoxaparin (subcutaneous) at doses demonstrated to be clinically effective in
acute coronary syndromes, or to serve as a control. Thrombin generation (prothrombin
fragment 12 [F12] and thrombin-antithrombin complex [TAT]) and platelet activation
(-thromboglobulin [-TG]) biomarkers were studied using a shed blood model involving
blood collection from skin incisions made using standardized bleeding time devices.
RESULTS Oral ximelagatran, intravenous r-hirudin and subcutaneous enoxaparin rapidly and signifi-
cantly (p 0.05) decreased F12, TAT and -TG levels in shed blood, indicating inhibition
of thrombin generation and platelet activation. Statistically significant concentration (mel-
agatran, the active form of ximelagatran)-response relationships for F12 (p  0.005), TAT
(p  0.005) and -TG (p  0.001) levels, with IC50s of 0.376 (F12), 0.163 (TAT) and
0.115 (-TG) mol/l, were detected. Melagatran showed dose-proportional pharmacokinet-
ics with low variability. All drugs were well tolerated.
CONCLUSIONS Oral administration of the DTI ximelagatran resulted in a rapid inhibition of both thrombin
generation and platelet activation in a concentration-dependent manner using a human shed
blood model. The inhibition of thrombin generation by 60 mg ximelagatran was comparable
to that observed with doses of r-hirudin and enoxaparin demonstrated to be effective for the
treatment of acute coronary syndromes. (J Am Coll Cardiol 2003;41:557–64) © 2003 by
the American College of Cardiology Foundation
Activation of the coagulation cascade by exposure of blood
to tissue factor results in a burst of thrombin formation,
which can rapidly lead to thrombus growth. Direct throm-
bin inhibitors (DTIs) block the activity of thrombin and
also have been shown to decrease the generation of throm-
bin via inhibition of thrombin’s positive feedback activation
of the coagulation cascade (1–3). In addition to its ability to
rapidly catalyze the formation of fibrin, thrombin is a potent
activator of platelets. Thrombin generation and platelet
activation have previously been studied in humans using an
in vivo shed blood model (1,4) that involves incision of the
forearm skin with standardized bleeding time devices, re-
sulting in exposure of blood to extravascular tissue factor
and rapid activation of both the coagulation cascade and
platelets (1,4).
Melagatran, the active form of the oral DTI ximelagat-
ran, is a potent thrombin inhibitor with a Ki for thrombin of
2 nmol/l (5,6). After oral administration, ximelagatran is
rapidly absorbed and converted to melagatran, with low
interindividual variability in melagatran plasma concentra-
tions (7). Ximelagatran is currently in clinical development
for the prevention and treatment of thromboembolic disor-
ders.
In an initial pilot study using the shed blood model, oral
ximelagatran (60 mg) and dalteparin (120 IU/kg) were
shown to inhibit thrombin generation (7). The present
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study was performed to expand upon these previous obser-
vations. The primary goal of the study was to investigate the
pharmacodynamic effects (thrombin generation and platelet
activation) of a range of doses of ximelagatran and paren-
teral doses of recombinant hirudin (r-hirudin) and enoxapa-
rin used in the treatment of acute coronary syndromes. The
secondary goals were to investigate the pharmacokinetics of
melagatran and the tolerability of oral ximelagatran. Addi-
tional investigations into the concentration (melagatran)-
response relationships for inhibition of thrombin generation
and platelet activation following oral ximelagatran were
carried out. The parenteral thrombin inhibitor r-hirudin
and the low molecular weight heparin (LMWH) enoxapa-
rin, at the doses used in this study, have been shown to be
effective antithrombotic drugs in large clinical studies of
acute coronary syndromes, including OASIS-2 (Organiza-
tion to Assess Strategies for Ischemic Syndromes) (8) and
ESSENCE (Efficacy and Safety of Subcutaneous Enoxapa-
rin in Non-Q-wave Coronary Events) (9).
Prothrombin fragment 12 (F12) is produced during
the final stage of thrombin formation, and thrombin-
antithrombin complex (TAT) reflects in vivo thrombin
generation processes. Prothrombin fragment 12 and TAT
were, therefore, used as biomarkers of thrombin generation.
Beta-thromboglobulin (-TG), an -granule protein se-
creted upon activation of platelets, was used as a biomarker
of platelet activation. Although these biomarkers cannot be
used for determination of clinical efficacy, understanding the
degree of inhibition of thrombin generation and platelet
activation may be useful for selecting effective doses of
antithrombotic drugs for study in patients with various
thromboembolic conditions.
METHODS
Subjects. Healthy male subjects age 19 to 40 years, with a
body mass index between 19 and 27 kg/m2 and from whom
informed consent was obtained before enrollment, were
included in this study. The subjects claimed not to have
ingested any prescribed medications, “over-the-counter”
drugs containing acetylsalicylic acid or nonsteroidal anti-
inflammatory drugs from two weeks before study initiation
until 48 h postdosing. This study was approved by the
University of Vienna Ethics Committee and was performed
in compliance with current good clinical practice guidelines
and the Declaration of Helsinki.
Study design. This was a randomized, open-label study
involving 120 subjects in six parallel groups (20 per group).
Each group received one of the following six treatments: a
single oral dose of ximelagatran (15, 30 or 60 mg); r-hirudin
(Refludan, Hoechst Marion Roussel, Frankfurt, Germany)
as a bolus intravenous (IV) injection (0.4 mg/kg), followed
by an IV infusion (0.15 mg/kg/h for 2 h plus 0.075 mg/kg/h
for 2 h); a single subcutaneous (SC) injection of enoxaparin
(100 U/kg; Klexane, Rhoˆne-Poulenc Rorer, Paris, France);
or an orally administered control (water). The IV infusion of
r-hirudin was given at high dose for only 2 h, followed by
2 h at a 50% lower infusion, in order to study the effects of
various concentrations of r-hirudin over time.
All subjects were given a complete health examination
(including physical examination, electrocardiogram and lab-
oratory screen) within 14 days of the study day and 2 to 5
days after the study day. The subjects were randomized to a
treatment group on the morning of the study day. The
subjects were compensated according to accepted local
practices and ethics committee approval.
Blood sampling. SHED BLOOD. The shed blood sampling
technique was performed as previously described (4,7) with
minor modifications. A sphygmomanometer was placed on
the upper arm and inflated to 45 mm Hg. A standardized
disposable device (Simplate IIR, Organon Technika Corp.,
Durham, North Carolina) was used to make two incisions
on the volar surface of the forearm (each 5-mm long and
1-mm deep) parallel to the antecubital crease. Shed blood
was collected predosing and 2, 4 and 10 h postdosing
directly from the edge of the incisions, starting immediately
after incision and until 4 min after incision, using an
automated plastic-tipped pipette. The blood was transferred
at approximately 30-s intervals during collection into ice-
cooled plastic tubes containing a stop solution consisting of
sodium citrate 3.8%, EDTA 100 mmol/l, indomethacin 30
mol/l, sodium heparin 1,500 U/ml, and aprotinin 1,000
U/ml, to prevent further thrombin generation or platelet
activation in the sample tube. After blood collection was
complete, the incisions were sealed using butterfly bandages.
The shed blood samples were centrifuged at 10,000  g for
5 min, and the plasma was separated and stored at 70°C
until analysis.
VENOUS BLOOD. Venous blood samples (4.5 ml) for the
measurement of F12, TAT and -TG were collected
predosing and 2, 4 and 10 h postdosing into stop solution
(described previously) at a 1:9 volume ratio to blood. The
samples were centrifuged at 3,000  g for 10 min, and the
plasma was separated and stored at 70°C until analysis.
Venous blood samples (4.5 ml) also were collected into
citrated tubes predosing and 1, 2, 3, 4, 6, 8, 10 and 12 h
Abbreviations and Acronyms
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DTI  direct thrombin inhibitor
ESSENCE  Efficacy and Safety of Subcutaneous
Enoxaparin in Non–Q-Wave Coronary
Events
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postdosing. A small amount of the citrated whole blood was
used to measure the activated partial thromboplastin time
(aPTT) in the ximelagatran groups. The remaining whole
blood was then centrifuged for 10 min at 1,500 g, and the
plasma separated and stored frozen (70°C) until determi-
nation of either plasma levels of melagatran (ximelagatran
groups) or anti-Xa activity (enoxaparin group).
Venous blood samples (3.5 ml) also were collected into
Figure 1. Geometric mean levels (95% confidence intervals) of prothrombin fragment 12 (F12) in shed blood from healthy male subjects by treatment
group predose and 2, 4 and 10 h postdosing. Statistical comparisons between the treatment and control groups have been made at each time point. *p value
 0.05 vs. control.
Figure 2. Geometric mean levels (95% confidence intervals) of thrombin-antithrombin complex (TAT) in shed blood from healthy male subjects by
treatment group predose and 2, 4 and 10 h postdosing. Statistical comparisons between the treatment and control groups have been made at each time point.
*p value  0.05 vs. control.
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tubes containing EDTA predosing and 2, 4, and 10 h
postdosing for determination of platelet count for normal-
ization of the -TG levels from IU/ml to IU/107 platelets.
Analyses. Prothrombin fragment 12, TAT and -TG
levels were determined in both venous and shed blood
samples using ELISA assays (Enzygnost F12 and
Enzygnost TAT, Behring Diagnostics GmbH, Marburg,
Germany; Asserachrom -TG, Diagnostica Stago,
Asnieres-sur-Seine, France).
Activated partial thromboplastin time was measured us-
ing individual TAS-aPTT assay cards and an automated
bedside (point of care) Thrombolytic Assessment System
(TAS, Pharmanetics Inc., Raleigh, North Carolina) card
reader as previously described (7). The TAS-aPTT device
generally overestimates conventional laboratory aPTT values.
Citrated plasma samples collected from the subjects who
received ximelagatran were analyzed for plasma levels of
melagatran using a liquid chromatography-mass spectrom-
etry method (10). Anti-Xa activity was determined using a
Coatest Heparin kit (Chromogenix AB, Mo¨lndal, Sweden).
For both melagatran (mol/l) and enoxaparin (anti-Xa
activity) the maximum plasma concentration (Cmax) and
time to maximum concentration (tmax) were estimated as
the highest measured plasma concentration and the time at
which that concentration was first measured, respectively.
The half-life (t1⁄2) was estimated as 0.693/k, where k
(elimination rate constant) was estimated by linear regres-
sion of the logarithm of plasma concentration versus time in
the linear portion of the elimination phase. For melagatran,
the area under the curve was calculated using the linear/log
trapezoidal rule up to the last measurable plasma concen-
tration and then extrapolated to infinity by addition of the
last measurable plasma concentration divided by the elimi-
nation rate constant (Clast/k).
Statistics. Prothrombin fragment 12, TAT and -TG
data were normalized by logarithmic transformation for the
statistical analyses. Statistical analyses of levels of these
biomarkers were performed using a repeated measures
analysis of variance with treatment and time as factors in the
Figure 3. Geometric mean levels (95% confidence intervals) of -thromboglobulin (-TG) in shed blood from healthy male subjects by treatment group
predose and 2, 4 and 10 h postdosing. Statistical comparisons between the treatment and control groups have been made at each time point. *p value 
0.05 vs. control.
Table 1. Ratios (95% CIs) of Shed Blood F12, TAT and
-TG Levels Between Comparator (r-hirudin and Enoxaparin)
Treatment Groups and 60 mg Ximelagatran Group
r-Hirudin:
60 mg Ximelagatran
Enoxaparin:
60 mg Ximelagatran
F12
0 h 1.04 (0.81, 1.34) 1.02 (0.80, 1.31)
2 h 0.88 (0.68, 1.13) 0.95 (0.74, 1.22)
4 h 0.89 (0.69, 1.14) 0.73 (0.57, 0.93)*
10 h 1.03 (0.80, 1.33) 0.98 (0.77, 1.26)
TAT
0 h 0.95 (0.75, 1.21) 0.90 (0.71, 1.13)
2 h 1.13 (0.89, 1.43) 1.58 (1.24, 2.00)*
4 h 1.21 (0.95, 1.54) 1.58 (1.25, 2.00)*
10 h 1.28 (1.00, 1.62)* 1.36 (1.07, 1.72)*
-TG
0 h 1.04 (0.79, 1.37) 1.02 (0.78, 1.34)
2 h 1.00 (0.76, 1.32) 2.16 (1.64, 2.85)*
4 h 0.91 (0.68, 1.22) 1.76 (1.33, 2.33)*
10 h 1.11 (0.84, 1.48) 1.53 (1.16, 2.02)*
*p  0.05 between groups.
CIs  confidence intervals; F12  prothrombin fragment 12; TAT 
thrombin-antithrombin complex; -TG  -thromboglobulin.
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model. Logarithmically transformed predose values were
used as a covariate in the model. Comparisons of between-
group effects at all measurement points were made and
presented with 95% confidence intervals (CIs). Group
differences were considered statistically significant at a level
of p  0.05 (two-tailed) when the 95% CIs of the ratios
excluded 1.0. Post hoc comparisons between the different
ximelagatran dose groups were performed using unpaired t
tests. No corrections have been made for the multiple
comparisons performed in this study. Point estimates and
variability are expressed as mean  standard deviation (SD)
unless otherwise indicated.
For the analysis of the concentration-effect relationship
(F12, TAT and -TG in shed blood), a repeated mea-
sures model adjusting for time since dose, predose levels and
interaction between dose and time since dose was used. No
interactions between time since dose and dose were de-
tected. An inhibitory concentration-response model was
also fit to the data using nonlinear regression and the
following equation: Effect  B0 * (1  [Cp/{Cp  IC50}]),
where B0  baseline response, Cp  plasma concentration,
and IC50  concentration resulting in 50% maximal inhi-
bition.
RESULTS
Effects on thrombin generation and platelet activation
biomarkers. Predose (0 h) shed blood F12, TAT and
-TG levels were comparable between treatment groups
(Figs. 1, 2, and 3, respectively). Statistically significant
decreases (p  0.05) in shed blood F12, TAT and/or
-TG levels were observed in all treatment groups at 2, 4
and/or 10 h postdosing compared with the control group
(Figs. 1 to 3).
Because the effects of both enoxaparin and r-hirudin on
shed blood F12, TAT and -TG levels appeared most
comparable to the effects following 60 mg ximelagatran,
additional comparisons of these groups with the 60 mg
ximelagatran group were made. No important differences on
the shed blood biomarkers were found between the 60 mg
ximelagatran and r-hirudin groups (Table 1). The reduction
in shed blood TAT with 60 mg ximelagatran was signifi-
cantly greater than with enoxaparin (p  0.05) at 2, 4 and
10 h postdosing, but the reduction in F12 was signifi-
cantly less than with enoxaparin (p  0.05) at 4 h postdos-
ing (Table 1). The reduction in shed blood -TG levels
following 60 mg ximelagatran was significantly greater than
those following enoxaparin (p  0.05) at 2, 4 and 10 h
postdosing (Table 1).
Post hoc analyses found the ximelagatran-induced de-
creases in shed blood F12, TAT and -TG levels to be
concentration (melagatran)-dependent. Statistically signifi-
cant relationships between concentration of melagatran and
the decrease in F12 (p  0.005), TAT (p  0.005) and
-TG (p  0.001) levels relative to predose were detected.
A nonlinear fit of the model parameters to the data is
shown in Figure 4, and the model parameters are shown in
Table 2.
Mean venous plasma F12, TAT and -TG levels did
not change over time, nor did they differ between groups,
with only a few exceptions (Table 3). There were no
changes in mean platelet count over time (predose to 10 h)
in any group (data not shown).
Activated partial thromboplastin time. Oral administra-
tion of ximelagatran resulted in a dose-dependent prolon-
gation of aPTT (Fig. 5). Regression analysis of transformed
data (aPTT-ratio vs. the square root of the plasma concen-
Figure 4. Geometric means (95% confidence intervals) of the ratios of the
prothrombin fragment 12 (F12), thrombin-antithrombin complex
(TAT) and -thromboglobulin (-TG) levels in shed blood collected after
administration of 15-, 30- and 60-mg oral doses of ximelagatran compared
with control (predose and 2, 4 and 10 h postdose) (n  12 per marker;
three doses  four time points). Predose ratios for each dose, when plasma
concentrations are zero, are plotted at 0.001 mol/l on the logarithmic
scale.
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tration of melagatran) produced a correlation coefficient
(R2) of 0.81.
Pharmacokinetics. Dose-proportional increases in the
Cmax of melagatran (0.12  0.02, 0.25  0.06 and 0.46 
0.10 mol/l) at a consistent tmax (1.9  0.4, 2.0  0.2 and
1.9  0.4 h) were observed following oral administration of
the 15-, 30- and 60-mg ximelagatran doses, respectively.
The area under the melagatran plasma concentration versus
time curves (AUC) for the 15-, 30- and 60-mg dose groups
also increased proportionally with dose (0.6  0.1, 1.3 
0.3 and 2.5  0.5 mol · h/l, respectively). The t1⁄2 of
melagatran in the ximelagatran 15-, 30- and 60-mg dose
groups was independent of dose (2.6  0.3, 2.8  0.3 and
2.8  0.3 h, respectively). The variability (coefficient of
variation, CV%) in Cmax, AUC, tmax and t1⁄2 (range of
means across doses) was 17% to 24%, 17% to 23%, 10% to
21% and 11% to 12%, respectively. The mean plasma
concentrations versus time profiles of melagatran after oral
administration of 15, 30 and 60 mg ximelagatran are shown
in Figure 6.
Administration of enoxaparin (100 U/kg SC) resulted in
an anti-Xa activity Cmax of 0.84  0.06 U/ml, a tmax of
3.3  0.7 h and a t1⁄2 of 5.0  1.1 h. The variability (CV%)
of Cmax, tmax and t1⁄2 was 7%, 21% and 20%, respectively.
Anti-Xa activity in the enoxaparin group predosing and 2, 4,
and 10 h postdosing was 0.02  0.02 U/ml, 0.79  0.08
U/ml, 0.83  0.06 U/ml and 0.42  0.07 U/ml, respec-
tively.
Tolerability. Ximelagatran, r-hirudin and enoxaparin were
all well tolerated with no laboratory abnormalities, bleeding
complications or serious adverse events reported in any of
the subjects during the study day.
DISCUSSION
Effects on thrombin generation and platelet activation.
Our results show that ximelagatran, r-hirudin and enoxapa-
rin inhibit thrombin generation and platelet activation using
the shed blood model. The inhibition by ximelagatran was
concentration (melagatran)-dependent. In the shed blood
model, thrombin generation and platelet activation are
initiated immediately after incision of the skin when blood
comes into contact with extravascular tissue factor (4,11,12).
Inhibition of thrombin generation by DTIs previously has
been reported to occur indirectly via inhibition of the
positive feedback activation of the coagulation cascade by
thrombin (1–3). The exact mechanism may depend largely
on inhibition of factor Va formation, because direct inhibi-
tion of thrombin decreases conversion of factor V to Va, and
factor Va appears to be a rate-limiting step in the formation
of the prothrombinase complex and thus in thrombin
generation (13).
The doses of r-hirudin and enoxaparin used in this study
have been demonstrated to be effective for the treatment of
acute coronary syndromes (8,9). However, in order to
investigate the effects of r-hirudin at lower blood concen-
Table 2. Model Parameters Generated by Fitting an Inhibitory
Concentration-Response Model by Nonlinear Regression
Response
Marker Parameter Estimate SE
F12 B0 1.021 0.033
IC50 (mol/l) 0.376 0.066
TAT B0 0.998 0.037
IC50 (mol/l) 0.163 0.025
-TG B0 0.925 0.026
IC50 (mol/l) 0.115 0.013
Parameters generated using the equation Effect  B0 * (1  [Cp/{Cp  IC50}]), where
B0  baseline response, Cp  plasma concentration, and IC50  concentration
resulting in 50% maximal inhibition. The standard errors (SE) are estimates of the
precision of the parameter estimates. The relative SE for B0 is 3% to 4% and for IC50
is 11% to 18%.
n  12 for each response marker; F12  prothrombin fragment 12; SE 
standard error; TAT  thrombin-antithrombin complex; -TG  -thrombo-
globulin.
Table 3. Ratios (95% CIs) of Venous F12, TAT and -TG Plasma Levels Between Treatment Groups and the Control Group
(Treatment/Control)
Ximelagatran
r-Hirudin Enoxaparin15 mg 30 mg 60 mg
F12
0 h 1.09 (0.86, 1.38) 0.96 (0.76, 1.21) 1.00 (0.79, 1.27) 0.90 (0.71, 1.14) 0.88 (0.69, 1.11)
2 h 0.85 (0.67, 1.08) 1.00 (0.79, 1.27) 0.79 (0.62, 1.00) 0.70* (0.56, 0.89) 0.71* (0.57, 0.90)
4 h 0.80 (0.63, 1.01) 0.97 (0.77, 1.23) 0.84 (0.67, 1.07) 0.67* (0.53, 0.85) 0.71* (0.56, 0.90)
10 h 0.86 (0.68, 1.09) 0.94 (0.74, 1.19) 0.91 (0.72, 1.15) 0.65* (0.51, 0.82) 0.81 (0.64, 1.02)
TAT
0 h 1.10 (0.80, 1.52) 1.05 (0.75, 1.46) 1.51* (1.07, 2.12) 1.29 (0.92, 1.81) 1.17 (0.84, 1.64)
2 h 0.93 (0.66, 1.29) 0.94 (0.67, 1.32) 1.09 (0.78, 1.54) 0.98 (0.70, 1.38) 0.88 (0.62, 1.25)
4 h 0.83 (0.60, 1.15) 0.91 (0.64, 1.28) 0.94 (0.67, 1.32) 0.89 (0.63, 1.26) 0.79 (0.55, 1.12)
10 h 0.94 (0.68, 1.31) 1.00 (0.71, 1.40) 1.22 (0.86, 1.72) 0.92 (0.65, 1.31) 0.90 (0.64, 1.27)
-TG
0 h 1.15 (0.73, 1.80) 0.84 (0.53, 1.32) 0.99 (0.63, 1.56) 1.03 (0.66, 1.62) 1.02 (0.65, 1.61)
2 h 0.85 (0.54, 1.33) 0.69 (0.44, 1.09) 0.57* (0.36, 0.90) 0.72 (0.46, 1.14) 0.63 (0.40, 1.00)
4 h 1.20 (0.76, 1.88) 1.41 (0.89, 2.25) 0.82 (0.52, 1.29) 1.06 (0.67, 1.66) 1.01 (0.63, 1.61)
10 h 0.91 (0.58, 1.43) 0.84 (0.53, 1.32) 0.57* (0.36, 0.90) 0.90 (0.57, 1.41) 0.68 (0.43, 1.07)
*p  0.05
F12  prothrombin fragment 12; TAT  thrombin-antithrombin complex; -TG  -thromboglobulin.
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trations in the present study, the infusion rate was halved
after 2 h and then stopped after 4 h. Because both r-hirudin
and enoxaparin have been shown to be effective in large
clinical studies of acute coronary syndromes, understanding
their effects on the shed blood biomarkers and comparing
these effects to a range of doses of ximelagatran was
considered valuable. Ximelagatran 60 mg appeared to most
closely match the inhibition of thrombin generation by
r-hirudin and enoxaparin. However, the effect of 60 mg
ximelagatran on inhibition of platelet activation was similar
to that of r-hirudin, but it was significantly better than that
of enoxaparin. Overall, these data suggest that doses of
ximelagatran up to 60 mg may be required for clinical
efficacy in acute coronary syndromes. These results also
suggest that, in this model, direct thrombin inhibition by
melagatran is superior for the inhibition of platelet activa-
tion to the indirect antithrombin-mediated inhibition of
thrombin by enoxaparin. Potential mechanistic explanations
for the superior effects on platelets observed with ximelagat-
ran include reduced occupancy of platelet thrombin recep-
tors by catalytically active thrombin and/or smaller molec-
ular size, allowing for easier access to clot-bound thrombin
(14).
It is interesting to note that 6 h after the stop of the IV
infusion of r-hirudin, which has a reported t1⁄2 of 1.3 h
(15), effects on thrombin generation and platelet activation
similar to those with 60 mg ximelagatran (t1⁄2 3 h) and
enoxaparin (t1⁄2 5 h) were observed. However, a longer
terminal t1⁄2 of 3 h for r-hirudin has been reported, which
may explain these observations (16).
Pharmacodynamic and pharmacokinetic effects. Our
data suggest that the inhibitory effects of ximelagatran and
Figure 5. Mean (SD) venous blood activated partial thromboplastin time (aPTT; using TAS-aPTT method) values vs. time since oral ximelagatran (15,
30 and 60 mg).
Figure 6. Mean (SD) melagatran plasma concentration (mol/l) vs. time since oral administration of 15-, 30- and 60-mg doses of ximelagatran (n  20
per group).
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the LMWHs enoxaparin and dalteparin (7) on thrombin
generation are very similar. Excluding the route of admin-
istration, ximelagatran and the LMWHs are also similar
from a pharmacokinetic point of view. The rapid peak in
melagatran plasma concentration following oral administra-
tion of ximelagatran is similar to that observed with the
LMWHs (tmax 2 to 3 h). This rapid onset of action suggests
that treatment of thromboembolism with ximelagatran can
be initiated rapidly without concomitant administration of
heparin or LMWH, in contrast to the current recom-
mended practice with the oral vitamin K antagonists, such
as warfarin (17). This approach is supported by findings
of a dose-guiding study with ximelagatran in patients
with deep vein thrombosis (18). The elimination half-
lives of melagatran and LMWHs are comparable, rang-
ing from 3 to 5 h (7,19 –21). In addition, the variability
in the pharmacokinetic parameters of melagatran follow-
ing oral administration of ximelagatran is relatively low
(25%) and comparable to that of parenterally adminis-
tered enoxaparin. Thus, if the shed blood technique is
predictive of an antithrombotic effect in patients, ximel-
agatran is likely to be effective where LMWHs are
effective.
Conclusions. Oral administration of the DTI ximelagat-
ran resulted in a rapid inhibition of both thrombin
generation and platelet activation in a concentration-
dependent manner using a human shed blood model.
The inhibition of thrombin generation by 60 mg
ximelagatran was comparable to that observed with
doses of r-hirudin and enoxaparin demonstrated to be
effective for the treatment of acute coronary syndromes.
The inhibition of platelet activation by 60 mg ximel-
agatran was comparable to that observed with r-hirudin
and superior to that observed with enoxaparin. Nu-
merous clinical trials with ximelagatran, including studies
in acute coronary syndrome patients, are currently ongo-
ing.
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